Starpharma receives TGA approval for VivaGel

Company News

by Jessica Amir

A developer of dendrimer products, Starpharma (ASX:SPL) has received Australian marketing approval from the Therapeutic Goods of Administration (TGA) for its product, VivaGel, that treats bacterial vaginosis.

Starpharma’s VivaGel is now expected to be available in pharmacies in the new year.

The product developed by Starpharma, will be marketed by Aspen Pharmacare as Fleurstat BV gel, carrying the VivaGel brand.

Aspen will also promote and distribute the product to clinicians and pharmacies in Australia and New Zealand.

Shares in Starpharma (ASX:SPL) are trading 3.36 per cent higher to $1.39.


Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 with a passion for equities and funds management. As Head of News, she has been a broadcast journalist for over seven years, specialising in finance. She has been a journalist with Sky News Business, ABC 1, ABC's The Business and ABC24. She’s also worked as a TV reporter for regional Channel 7 and 9. She also previously worked as a financial planner and real estate agent.